Key Considerations Before Investing in Merck & Co. (MRK)

Shares of Health Care sector company Merck & moved -4.6% today, and are now trading at a price of $123.8. The Large-Cap stock's daily volume was 12,004,765 compared to its average volume of 7,497,525. The S&P 500 index returned a -0.0% performance.

Merck & Co., Inc. operates as a healthcare company worldwide. The company is based in Rahway and has 70,000 full time employees. Its market capitalization is $313,561,874,432. Merck & currently offers its equity investors a dividend that yields 2.3% per year.

25 analysts are following Merck & and have set target prices ranging from $124.5 to $155.0 per share. On average, they have given the company a rating of buy. At today's prices, MRK is trading -13.41% away from its average analyst target price of $142.98 per share.

Over the last year, MRK's share price has increased by 12.5%, which represents a difference of -10.7% when compared to the S&P 500. The stock's 52 week high is $134.63 per share whereas its 52 week low is $99.14. With average free cash flows of $12.45 Billion that have been growing at an average rate of 24.1% over the last 5 years, Merck & is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 13,006,000 14,083,000 27,089,000 84.19
2022 19,095,000 4,388,000 14,707,000 69.55
2021 13,122,000 4,448,000 8,674,000 48.94
2020 10,253,000 4,429,000 5,824,000 -42.17
2019 13,440,000 3,369,000 10,071,000 21.24
2018 10,922,000 2,615,000 8,307,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.